Drug intelligence / Profile preview

OG253

Development stage: Unknown
Lead developer: Oragenics
Modality: Antimicrobial Peptides → Native Peptides → Peptides
Administration: Oral

Overview

OG253 is a **lantibiotic** derived from the Mutacin 1140 variant and is being developed for the treatment of **Clostridium difficile-associated disease (CDAD)**. It has shown efficacy in reducing the severity of CDAD and preventing recurrence in animal models. OG253 is not absorbed into the bloodstream, acting locally in the gastrointestinal tract. It has demonstrated a unique mechanism of action and low toxicity in preclinical studies.

Other names: MU1140 (Phe1Ile) variant

Targets

Lipid II

Beyond the preview

Go deeper on OG253.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OG253.

Explore the full profile